[{"id":"0c45dd0e-f439-463b-8d1f-a9be494b9943","acronym":"","url":"https://clinicaltrials.gov/study/NCT02808650","created_at":"2021-01-18T13:46:35.607Z","updated_at":"2024-07-02T16:35:25.681Z","phase":"Phase 1","brief_title":"Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors","source_id_and_acronym":"NCT02808650","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":" | ","alterations":" TP53 mutation • TP53 deletion • TP53 expression","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 deletion • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/27/2017","start_date":" 02/27/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 03/31/2021","study_completion_date":" 03/31/2021","last_update_posted":"2023-12-20"},{"id":"931391bf-b0d8-47a7-96c3-13986b5a3f13","acronym":"ExIST","url":"https://clinicaltrials.gov/study/NCT04032080","created_at":"2021-03-26T18:56:03.697Z","updated_at":"2024-07-02T16:35:37.448Z","phase":"Phase 2","brief_title":"LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT04032080 - ExIST","lead_sponsor":"Baylor Research Institute","biomarkers":" ER","pipe":" | ","alterations":" ER negative","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368) • samotolisib (LY3023414)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 09/05/2019","start_date":" 09/05/2019","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 11/26/2022","study_completion_date":" 11/26/2022","last_update_posted":"2023-09-11"},{"id":"b2d3e38f-bf00-4920-aff3-f61daeca6754","acronym":"","url":"https://clinicaltrials.gov/study/NCT02873975","created_at":"2021-01-18T14:06:40.199Z","updated_at":"2024-07-02T16:36:02.020Z","phase":"Phase 2","brief_title":"A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency","source_id_and_acronym":"NCT02873975","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA1 • BRCA2 • MYC • CCNE1 • FBXW7 • CHEK2 • RAD51C • RAD51D","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • MYC amplification • PALB2 mutation • CCNE1 amplification • FBXW7 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • MYC • CCNE1 • FBXW7 • CHEK2 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • MYC amplification • PALB2 mutation • CCNE1 amplification • FBXW7 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 10/12/2016","start_date":" 10/12/2016","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 07/01/2021","study_completion_date":" 07/01/2021","last_update_posted":"2022-10-21"},{"id":"ab89eaa8-41e6-4795-980c-7b432823a078","acronym":"","url":"https://clinicaltrials.gov/study/NCT03414047","created_at":"2021-01-18T16:50:37.257Z","updated_at":"2024-07-02T16:36:05.182Z","phase":"Phase 2","brief_title":"A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03414047","lead_sponsor":"Eli Lilly and Company","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368)"],"overall_status":"Completed","enrollment":" Enrollment 172","initiation":"Initiation: 04/10/2018","start_date":" 04/10/2018","primary_txt":" Primary completion: 06/03/2019","primary_completion_date":" 06/03/2019","study_txt":" Completion: 10/03/2020","study_completion_date":" 10/03/2020","last_update_posted":"2022-08-19"},{"id":"b3a48768-ed71-493b-a904-634739217a2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03057145","created_at":"2021-01-18T15:03:26.356Z","updated_at":"2025-02-25T14:57:51.725Z","phase":"Phase 1","brief_title":"Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03057145","lead_sponsor":"Geoffrey Shapiro, MD, PhD","biomarkers":" BRCA1 • BRCA2 • RAD51 • H2AX","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • RAD51 • H2AX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • prexasertib (ACR-368)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 03/10/2017","start_date":" 03/10/2017","primary_txt":" Primary completion: 02/25/2020","primary_completion_date":" 02/25/2020","study_txt":" Completion: 06/09/2021","study_completion_date":" 06/09/2021","last_update_posted":"2021-09-02"},{"id":"f0cb7650-9cf7-4124-9324-f18c9ca76aca","acronym":"","url":"https://clinicaltrials.gov/study/NCT03495323","created_at":"2021-01-18T17:12:40.498Z","updated_at":"2024-07-02T16:36:31.922Z","phase":"Phase 1","brief_title":"A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03495323","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" PD-L1 • H2AX","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • H2AX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368) • lodapolimab (LY3300054)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/16/2018","start_date":" 05/16/2018","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2021-04-15"},{"id":"a7f30cb8-462c-4f77-a391-48ab885c8c71","acronym":"","url":"https://clinicaltrials.gov/study/NCT02124148","created_at":"2021-01-18T09:50:31.965Z","updated_at":"2024-07-02T16:36:47.033Z","phase":"Phase 1b","brief_title":"A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer","source_id_and_acronym":"NCT02124148","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • KRAS • ER • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 overexpression • PIK3CA mutation • KRAS wild-type • RAS wild-type • ER negative • PGR negative","tags":["HER-2 • KRAS • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • PIK3CA mutation • KRAS wild-type • RAS wild-type • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • 5-fluorouracil • pemetrexed • prexasertib (ACR-368) • leucovorin calcium • samotolisib (LY3023414)"],"overall_status":"Completed","enrollment":" Enrollment 167","initiation":"Initiation: 06/18/2014","start_date":" 06/18/2014","primary_txt":" Primary completion: 02/13/2020","primary_completion_date":" 02/13/2020","study_txt":" Completion: 02/13/2020","study_completion_date":" 02/13/2020","last_update_posted":"2020-04-01"},{"id":"fa0366b2-b77f-4189-a5a6-884d66f42b34","acronym":"","url":"https://clinicaltrials.gov/study/NCT02860780","created_at":"2021-01-18T14:02:35.003Z","updated_at":"2024-07-02T16:37:04.664Z","phase":"Phase 1","brief_title":"A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer","source_id_and_acronym":"NCT02860780","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368) • ralimetinib (LY 2228820)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 08/10/2016","start_date":" 08/10/2016","primary_txt":" Primary completion: 05/15/2017","primary_completion_date":" 05/15/2017","study_txt":" Completion: 05/15/2017","study_completion_date":" 05/15/2017","last_update_posted":"2018-12-14"}]